- Home
- VKTX vs MLTX Comparison
VKTX vs MLTX Comparison
Compare VKTX & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VKTX
- MLTX
- Stock Information
- Founded
- VKTX 2012
- MLTX 2021
- Country
- VKTX United States
- MLTX Switzerland
- Employees
- VKTX N/A
- MLTX N/A
- Industry
- VKTX Biotechnology: Pharmaceutical Preparations
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- VKTX Health Care
- MLTX Health Care
- Exchange
- VKTX Nasdaq
- MLTX Nasdaq
- Market Cap
- VKTX 2.8B
- MLTX 2.3B
- IPO Year
- VKTX 2015
- MLTX N/A
- Fundamental
- Price
- VKTX $27.55
- MLTX $38.60
- Analyst Decision
- VKTX Buy
- MLTX Strong Buy
- Analyst Count
- VKTX 12
- MLTX 8
- Target Price
- VKTX $84.00
- MLTX $80.50
- AVG Volume (30 Days)
- VKTX 4.3M
- MLTX 423.9K
- Earning Date
- VKTX 04-23-2025
- MLTX 05-20-2025
- Dividend Yield
- VKTX N/A
- MLTX N/A
- EPS Growth
- VKTX N/A
- MLTX N/A
- EPS
- VKTX N/A
- MLTX N/A
- Revenue
- VKTX N/A
- MLTX N/A
- Revenue This Year
- VKTX N/A
- MLTX $103.42
- Revenue Next Year
- VKTX N/A
- MLTX N/A
- P/E Ratio
- VKTX N/A
- MLTX N/A
- Revenue Growth
- VKTX N/A
- MLTX N/A
- 52 Week Low
- VKTX $18.92
- MLTX $31.42
- 52 Week High
- VKTX $81.81
- MLTX $58.26
- Technical
- Relative Strength Index (RSI)
- VKTX 53.68
- MLTX 53.31
- Support Level
- VKTX $26.37
- MLTX $36.75
- Resistance Level
- VKTX $30.28
- MLTX $42.90
- Average True Range (ATR)
- VKTX 1.65
- MLTX 2.06
- MACD
- VKTX 0.27
- MLTX 0.03
- Stochastic Oscillator
- VKTX 56.53
- MLTX 58.04
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.